Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: mlkr who wrote (2928)	6/15/2010 10:46:20 AM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ATRC opened with a good UG after announcing yesterday AHs that it received FDA clearance for its AtriClip Gillinov-Cosgrove Left Atrial Appendage Exclusion system. <g> The stock was up 37.66% and is still up 24.47% at present on volume >785Ks which is about 12x its ADV bigcharts.marketwatch.com The launch of the AtriClip system in the US is expected to start later this month. The AtriClip system provides a safe method to exclude the left atrial appendage. Stagnant blood within the trabeculations of the atrial apendage form clots that can then embolize to the brain or other important organs. The AtriClip is designed to be implanted from the outside of the heart and it eliminates blood flow between the left atrial appendage and the atria. It has been now cleared by the FDA for occlusion of the left atrial appendage, under direct visualization, in conjunction with other open-heart cardiac procedures. <g> The ACTAY is $7.64 The EL for the current Yr. is around $0.40 vs. $0.39 in 2009 It seems that with some good news the stock could get to test the resistance at the $10 level.<g> bigcharts.marketwatch.com Bernard

To: mlkr who wrote (2928)	8/26/2010 11:51:09 AM
From: Jibacoa	Respond to of 3722

MRNA is trying to move up after forming a base at the $2.55 level.<g> The stock is up 9.66% with volume now > 3/4 its ADV bigcharts.marketwatch.com MRNA announced today that it has entered into an Agreement with CYPB under which CYPB will acquire MMRNA's patent rights and technology related to Carbetocin. MRNA will receive an upfront payment of $750,000 and potential milestone payments up to $27M and CYPB will be responsible for all future development and related expenses and will pay MRNA royalties on commercial sales. MRNA's CEO said: "The sale of our Carbetocin assets is another example of our efforts to monetize the legacy assets of our predecessor company while we remain focused on building value around our RNAi drug discovery platforms." Now have to watch the resistance at the $4 level.<g> Bernard